Advertisement

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. FDA approves first non-controlled substance narcolepsy drug
  2. NICE approves Keytruda combination therapy for NSCLC through CDF
  3. Novartis defends Zolgensma in face of FDA’s data concerns
  4. Through time: the breakthroughs changing the course of HIV treatment
  5. Trouble at Teva: US price-fixing lawsuit adds to generic giant’s woes

Latest Content

NICE approves Keytruda combination therapy for NSCLC through CDF

The UK’s healthcare regulator the National Institute of Health and Care Excellence (NICE) has recommended Merck’s Keytruda (pembrolizumab) combined with two chemotherapy drugs, carboplatin and paclitaxel or nabpaclitaxel, be made immediately available to National Health Service (NHS) non-small cell lung cancer (NSCLC) patients through the Cancer Drugs Fund (CDF).

Through time: the breakthroughs changing the course of HIV treatment

This has been a landmark year for HIV treatment; a seven-year study confirmed that taking ART can prevent transmission between gay couples and a second patient has been effectively cured of HIV after receiving a stem cell transplant as a cancer treatment. Allie Nawrat tracks progress in the decades-long quest to effectively prevent, treat and attempt to cure the disease.

July’s top news stories

Zirabev gets FDA approval to treat five types of cancer and Dundee University and Bukwang to develop Parkinson’s drug. Pharmaceutical-technology.com wraps up key headlines from June 2019.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Close
Close
Close

Go Top